Spinal Muscular Atrophy (SMA) – Market Insight, Epidemiology and Market Forecast 2019-2032: Featuring Players Roche, Novartis and Biogen Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Spinal Muscular Atrophy (SMA) – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering.

This “Spinal Muscular Atrophy (SMA)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Spinal Muscular Atrophy (SMA), historical and forecasted epidemiology as well as the Spinal Muscular Atrophy (SMA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spinal Muscular Atrophy (SMA) market report provides current treatment practices, emerging drugs, Spinal Muscular Atrophy (SMA) market share of the individual therapies, current and forecasted Spinal Muscular Atrophy (SMA) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Spinal Muscular Atrophy (SMA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market

Spinal Muscular Atrophy (SMA) Disease Understanding and Treatment Algorithm

The Spinal Muscular Atrophy (SMA) market report gives a thorough understanding of Spinal Muscular Atrophy (SMA) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Spinal Muscular Atrophy (SMA) Epidemiology

The Spinal Muscular Atrophy (SMA) epidemiology division provide insights about historical and current Spinal Muscular Atrophy (SMA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Spinal Muscular Atrophy (SMA) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Spinal Muscular Atrophy (SMA) Drug Chapters

Drug chapter segment of the Spinal Muscular Atrophy (SMA) report encloses the detailed analysis of Spinal Muscular Atrophy (SMA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Spinal Muscular Atrophy (SMA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Spinal Muscular Atrophy (SMA) treatment.

Spinal Muscular Atrophy (SMA) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Spinal Muscular Atrophy (SMA) treatment.

Spinal Muscular Atrophy (SMA) Market Outlook

The Spinal Muscular Atrophy (SMA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Spinal Muscular Atrophy (SMA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Spinal Muscular Atrophy (SMA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Spinal Muscular Atrophy (SMA) market in 7MM is expected to change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Spinal Muscular Atrophy (SMA) market in 7MM.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Spinal Muscular Atrophy (SMA) Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Spinal Muscular Atrophy (SMA), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Spinal Muscular Atrophy (SMA) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Spinal Muscular Atrophy (SMA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Spinal Muscular Atrophy (SMA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Spinal Muscular Atrophy (SMA) market

Report Highlights

• In the coming years, Spinal Muscular Atrophy (SMA) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Spinal Muscular Atrophy (SMA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Spinal Muscular Atrophy (SMA). Launch of emerging therapies will significantly impact the Spinal Muscular Atrophy (SMA) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Spinal Muscular Atrophy (SMA)

Key Topics Covered:

1. Key Insights

2. Executive Summary of Spinal Muscular Atrophy (SMA)

3. Competitive Intelligence Analysis for Spinal Muscular Atrophy (SMA)

4. Spinal Muscular Atrophy (SMA): Market Overview at a Glance

4.1. Spinal Muscular Atrophy (SMA) Total Market Share (%) Distribution in 2019

4.2. Spinal Muscular Atrophy (SMA) Total Market Share (%) Distribution in 2032

5. Spinal Muscular Atrophy (SMA): Disease Background and Overview

6. Patient Journey

7. Spinal Muscular Atrophy (SMA) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.4. United States Epidemiology

7.5. EU-5 Country-wise Epidemiology

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Spinal Muscular Atrophy (SMA) Treatment and Management

8.2. Spinal Muscular Atrophy (SMA) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Spinal Muscular Atrophy (SMA) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Spinal Muscular Atrophy (SMA): Seven Major Market Analysis

13.1. Key Findings

13.2. Spinal Muscular Atrophy (SMA) Market Size in 7MM

13.3. Spinal Muscular Atrophy (SMA) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.4. France Market Size

15.5. Italy Market Size

15.6. Spain Market Size

15.7. United Kingdom Market Size

15.8. Japan Market Outlook

16. Access and Reimbursement Overview of Spinal Muscular Atrophy (SMA)

17. KOL Views

18. Market Drivers

19. Market Barriers

Companies Mentioned

• Cytokinetics
• Roche
• Avexis
• Novartis
• Biogen 

For more information about this report visit https://www.researchandmarkets.com/r/mm0vb9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900